Louis Plamondon is a recognized leader in the discovery, development and commercialization of small molecule drugs. He is a passionate scientist with experience leading multidisciplinary teams and overseeing programs across several therapeutic areas and development stages.

Prior to joining LifeMine, Louis was SVP and Head of CMC at Constellation Pharmaceuticals (a MorphoSys company) where he led  all pre-development/development activities including production of Drug Substance and Drug Product for pre-clinical studies, toxicology studies, clinical studies, and preparations for commercialization.

His expertise ranges from enabling Phase I studies through global registrational application and includes commercial manufacturing and launch activities. His impressive influence includes establishing clinical and commercial supply chain strategies, vendor and alliance management, portfolio strategy implementation, developing regulatory strategies, negotiating with global health authorities, developing life-cycle management strategies and generating secondary patents to extend product life-cycle.

Some of his key contributions include being a co-inventor and leader for Velcade^® (bortezomib), the first proteasome inhibitor approved for the treatment of patients with multiple myeloma, and co-inventor for Xerava^® (Eravacycline), the first fully synthetic fluorocycline used for the treatment of complicated intra-abdominal infections (cIAI).

Louis earned his Ph.D. in Organic Chemistry from the Université de Montréal under the guidance of James D. Wuest and completed his postdoctoral fellowship at Harvard University under the guidance of Stuart L. Schreiber.